- Potential benefitReduces regulatory compliance burdens by preventing IRIS-based standards that could trigger new controls.
- Potential benefitSupports use of alternative data sources that proponents may deem more current or transparent.
- Potential benefitMay lower perceived regulatory risk and litigation tied specifically to IRIS-based determinations.
No IRIS Act of 2025
Read twice and referred to the Committee on Environment and Public Works.
The bill prohibits the EPA Administrator from using any assessment produced by the EPA’s Integrated Risk Information System (IRIS) program as a basis to develop, finalize, or issue rules or regulations, to carry out regulatory, enforcement, or permitting actions, or to inform air toxics assessments, mapping, or screening tools.
Progressives emphasize public-health harms from blocking IRIS.
Narrow, administratively focused bills often advance in the House, but controversy over science/regulation raises opposition risk.
The bill prohibits the EPA Administrator from using any assessment produced by the EPA’s Integrated Risk Information System (IRIS) program as a basis to develop, finalize, or issue rules or regulations, to carry out regulatory, enforcement, or permitting actions, or to inform air toxics assessments, mapping, or screening tools.
Narrow and administratively focused but ideologically charged and lacking compromise features, reducing cross-chamber and cross-branch appeal.
How solid the drafting looks.
Progressives emphasize public-health harms from blocking IRIS.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- CitiesReduces EPA access to a centralized, peer-reviewed toxicity assessment resource used in health-based rulemaking.
- Potential burdenCould delay or weaken pollution controls, increasing population exposures and potential adverse health outcomes.
- Potential burdenMay force reliance on disparate alternative studies, increasing regulatory inconsistency and legal vulnerability.
Why the argument around this bill splits.
Progressives emphasize public-health harms from blocking IRIS.
Likely to view the bill as a rollback of an EPA scientific tool that supports health-based regulation.
They will argue it undermines public-health protections by barring use of agency risk assessments in rulemaking and enforcement.
Will have mixed views: sympathetic to concerns about scientific rigor and legal defensibility, but worried about public-health gaps.
They will weigh procedural improvements against the risk of regulatory paralysis.
Likely to view the bill favorably as a constraint on EPA regulatory power and as a measure to prevent agency reliance on possibly over-conservative internal assessments.
They will frame it as reducing regulatory burden on industry.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow and administratively focused but ideologically charged and lacking compromise features, reducing cross-chamber and cross-branch appeal.
- Whether IRIS assessments are precisely defined for enforcement
- Effect on existing or in-progress EPA rules is unclear
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize public-health harms from blocking IRIS.
Narrow and administratively focused but ideologically charged and lacking compromise features, reducing cross-chamber and cross-branch appe…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for No IRIS Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.